Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: A systematic review and meta-analysis
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2016 |
|---|---|
| Enthalten in: |
Expert opinion on drug safety - (2016) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Haguet, Hélène [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1080/14740338.2017.1261824 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1986349144 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1986349144 | ||
| 003 | DE-627 | ||
| 005 | 20230518142654.0 | ||
| 007 | tu | ||
| 008 | 161202s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14740338.2017.1261824 |2 doi | |
| 028 | 5 | 2 | |a PQ20161201 |
| 035 | |a (DE-627)OLC1986349144 | ||
| 035 | |a (DE-599)GBVOLC1986349144 | ||
| 035 | |a (PRQ)crossref_primary_10_1080_14740338_2017_12618240 | ||
| 035 | |a (KEY)0509195020160000000000000000riskofarterialandvenousocclusiveeventsinchronicmye | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Haguet, Hélène |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: A systematic review and meta-analysis |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 700 | 1 | |a Douxfils, Jonathan |4 oth | |
| 700 | 1 | |a Mullier, François |4 oth | |
| 700 | 1 | |a Chatelain, Christian |4 oth | |
| 700 | 1 | |a Graux, Carlos |4 oth | |
| 700 | 1 | |a Dogné, Jean-Michel |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d London : Informa Healthcare, 2002 |g (2016) |w (DE-627)354542478 |w (DE-600)2088728-0 |w (DE-576)435515020 |x 1474-0338 |7 nnns |
| 773 | 1 | 8 | |g year:2016 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1080/14740338.2017.1261824 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |j 2016 | ||